ES8608532A1 - Procedimiento para la preparacion de gangliosidos y sus derivados administrables por nebulizacion - Google Patents

Procedimiento para la preparacion de gangliosidos y sus derivados administrables por nebulizacion

Info

Publication number
ES8608532A1
ES8608532A1 ES537300A ES537300A ES8608532A1 ES 8608532 A1 ES8608532 A1 ES 8608532A1 ES 537300 A ES537300 A ES 537300A ES 537300 A ES537300 A ES 537300A ES 8608532 A1 ES8608532 A1 ES 8608532A1
Authority
ES
Spain
Prior art keywords
kit
inhalation
derivatives
pharmaceutical compositions
compositions suitable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES537300A
Other languages
English (en)
Other versions
ES537300A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia SpA
Original Assignee
Fidia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia SpA filed Critical Fidia SpA
Publication of ES537300A0 publication Critical patent/ES537300A0/es
Publication of ES8608532A1 publication Critical patent/ES8608532A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Otolaryngology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PREPARACION DE GANGLIOSIDOS COMO TALES O EN FORMA DE SALES, PARA SU ADMINISTRACION POR INHALACION. CONSISTE EN EXTRAER EL GANGLIOSIDO Y CONVERTIR SUS GRUPOS CARBOXILATO EN CARBOXILO, AYUDANDOSE DE UN REACTIVO DE LACTONIZACION PARA FORMAR EL DERIVADO DE ESTER. ESTE DERIVADO PUEDE SER MEZCLADO CON UN EXCIPIENTE ACUOSO PARA CONSTITUIR UNA FORMULACION DE NEBULIZACION, CON UN PROPULSOR PARA FORMULACION AEROSOL O CON UN EXCIPIENTE SOLIDO PARA INHALACION. EL COMPUESTO PUEDE IR ACOMPAÑADO DE OTROS INGREDIENTES ACTIVOS, COMO BRONCODILATADORES. SE UTILIZAN PARA EL TRATAMIENTO DE DESORDENES DEL SISTEMA NERVIOSO, EN LOS QUE ESTE DAÑADO EL TEJIDO NERVIOSO.
ES537300A 1983-11-08 1984-10-31 Procedimiento para la preparacion de gangliosidos y sus derivados administrables por nebulizacion Expired ES8608532A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8349288A IT1212896B (it) 1983-11-08 1983-11-08 Metodo di somministrazione per via inalatoria di gangliosidi e derivati, e composizioni farmaceutiche relative

Publications (2)

Publication Number Publication Date
ES537300A0 ES537300A0 (es) 1986-07-16
ES8608532A1 true ES8608532A1 (es) 1986-07-16

Family

ID=11270228

Family Applications (1)

Application Number Title Priority Date Filing Date
ES537300A Expired ES8608532A1 (es) 1983-11-08 1984-10-31 Procedimiento para la preparacion de gangliosidos y sus derivados administrables por nebulizacion

Country Status (22)

Country Link
US (1) US4639437A (es)
EP (1) EP0145209B1 (es)
JP (1) JPS60132920A (es)
KR (1) KR850003503A (es)
AT (1) ATE47035T1 (es)
AU (1) AU569920B2 (es)
BE (1) BE900994A (es)
CH (1) CH662278A5 (es)
DE (1) DE3480053D1 (es)
DK (1) DK160129C (es)
ES (1) ES8608532A1 (es)
FR (1) FR2554346B1 (es)
GR (1) GR80853B (es)
IL (1) IL73292A (es)
IN (1) IN163563B (es)
IT (1) IT1212896B (es)
LU (1) LU85633A1 (es)
MX (1) MX163574B (es)
NO (1) NO844443L (es)
NZ (1) NZ209974A (es)
PT (1) PT79466B (es)
ZA (1) ZA848541B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1177863B (it) * 1984-07-03 1987-08-26 Fidia Farmaceutici Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche
JPS6368526A (ja) * 1986-09-11 1988-03-28 Mect Corp シアリルグリセライドからなる神経障害疾患治療剤
US4937232A (en) * 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
IT1212041B (it) * 1987-11-02 1989-11-08 Fidia Farmaceutici Gangliosidi esteri interni come agenti terapeutici capaci di eliminare il dolore nelle neuropatie periferiche
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US6407061B1 (en) 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
ATE156704T1 (de) * 1989-12-05 1997-08-15 Ramsey Foundation Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
IT1249034B (it) * 1990-06-29 1995-02-11 Fidia Spa Impiego del monosialoganglioside gm1 e del suo derivato estere interno per impedire l'instaurarsi della tolleranza nell'uomo all'effetto analgesico della morfina e analoghi
WO1992017189A1 (en) * 1991-03-29 1992-10-15 The Regents Of The University Of California Gangliosides with immunosuppressive activity
WO1993002686A1 (en) * 1991-07-31 1993-02-18 The Regents Of The University Of California Gangliosides with immunosuppressive ceramide moieties
US5567684A (en) * 1994-09-14 1996-10-22 The Regents Of The University Of California Synthetic ganglioside derivatives
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
EP1435972B1 (en) 2001-08-29 2016-03-09 Seneb Biosciences Inc. Novel synthetic ganglioside derivatives and compositions thereof
AU2004220087A1 (en) 2003-03-06 2004-09-23 Seneb Biosciences, Inc. Methods and compositions for the enzymatic synthesis of gangliosides
CU23317A1 (es) 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
EP2410846B1 (en) 2009-03-25 2016-09-07 Seneb Biosciences, Inc. Glycolipids as treatment for disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL262354A (es) * 1960-03-17
US3282781A (en) * 1960-11-25 1966-11-01 Merck & Co Inc Inhalant compositions
US4094968A (en) * 1972-09-06 1978-06-13 Burroughs Wellcome Co. Treatment for allergy and method of composition thereof
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
US4476119A (en) * 1981-08-04 1984-10-09 Fidia S.P.A. Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions

Also Published As

Publication number Publication date
DE3480053D1 (en) 1989-11-16
ES537300A0 (es) 1986-07-16
ZA848541B (en) 1985-06-26
IT8349288A0 (it) 1983-11-08
EP0145209A3 (en) 1986-11-26
MX163574B (es) 1992-06-02
DK160129C (da) 1991-07-01
NZ209974A (en) 1987-02-20
ATE47035T1 (de) 1989-10-15
IT1212896B (it) 1989-11-30
PT79466A (en) 1984-12-01
FR2554346A1 (fr) 1985-05-10
IL73292A0 (en) 1985-01-31
GR80853B (en) 1985-02-26
EP0145209B1 (en) 1989-10-11
NO844443L (no) 1985-05-09
IL73292A (en) 1988-07-31
US4639437A (en) 1987-01-27
KR850003503A (ko) 1985-06-20
AU3518984A (en) 1985-05-16
JPH0211570B2 (es) 1990-03-14
LU85633A1 (fr) 1985-06-04
DK160129B (da) 1991-02-04
CH662278A5 (fr) 1987-09-30
BE900994A (nl) 1985-05-07
PT79466B (en) 1986-12-12
FR2554346B1 (fr) 1987-11-20
DK505584D0 (da) 1984-10-23
EP0145209A2 (en) 1985-06-19
AU569920B2 (en) 1988-02-25
DK505584A (da) 1985-05-09
JPS60132920A (ja) 1985-07-16
IN163563B (es) 1988-10-08

Similar Documents

Publication Publication Date Title
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
IL133585A0 (en) Soluble prodrugs of paclitaxel
ZA848369B (en) Pharmaceutical compositions containing bilobalid for the treatment of neuropathies
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
IL68456A0 (en) Pharmaceutical compositions comprising perfluorohydrocarbons as vehicles
GB9212308D0 (en) Therapeutic compositions
IL85963A0 (en) Pharmaceutical compositions for the prophylaxis or treatment of disorders or diseases of the gastrointestinal tract,comprising antigenic substances
GB2162748B (en) Medicinal composition for the treatment or prevention of acne by oral administration
ZA875847B (en) Pharmaceutical compositions for the treatment of occlusive vascular diseases
GB2204488B (en) Pharmaceutical compositions for the treatment or prophylaxis of skin disorders
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
JPS5753475A (en) Novel thiazolyl-2-oxamic acid derivative, manufacture and medicine containing same
HUT73500A (en) Use of benzydamine for producing pharmaceutical compositions for treatment of pathological conditions caused by tnf
DK0950053T3 (da) Hidtil ukendte benzoylalkyl.1,2,3,6-tetrahydropyridinderivater
IT8249521A0 (it) Composizioni farmaceutiche contenenti idrossicicloesilammine da usare nel trattamento di malattie respiratorie
AP9000180A0 (en) Pharmaceutical composition for the treatment of protozoal diseases
ZA896464B (en) Use of 2-azabicyclo(2.2.2)octane-3-carboxylic acid derivatives for the production of medicinal products intended for the treatment of diseases resulting from impairment of the vascular wall as well as for disorders of the microcirculation
ZA897549B (en) Medicament for the treatment of diseases caused by retroviruses
UA10093A (uk) Спосіб лікування захворювань товстої кишки
ZA925983B (en) Pharmaceutical compositions for the treatment of skin disorders
ATE94758T1 (de) Verwendung von gangliosiden zur behandlung der dysfunktion des autonomen nervensystems bei der chagas-krankheit.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970519